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Rate of adverse events of medium-to high dose glucocorticoid therapy in Systemic Lupus 
Erythematous: a systematic review  
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Abstract 
The efficacy of glucocorticoids (GCs) in treating Systemic Lupus Erythematous (SLE) is beyond doubt. 
However, GCs-related adverse events (AEs) are multiples and serious. Despite the current available 
evidences suggesting to reduce daily doses of prednisone <7.5 mg/day, or even to withdraw it, in the 
real-life practice, it is not uncommon to see patients receiving medium doses (up to 30 mg/day 
prednisone or equivalent) or high doses (≥30 mg/day). In this systematic review we assessed the rate 
of AEs related to medium or high dose of GCs in patients with SLE, analysing randomised control trials 
with at least one of the treatment groups including GCs alone at medium doses or high doses. We 
found a rate of 9/100patients/year for hyperglycaemias/diabetes, 25/100patients/year infections, 
and 12/100patients/year for avascular necrosis of the hip. Interestingly, when adjusting for CGs dose  
and treatment duration, we observed no difference in terms of AEs rate comparing patients receiving 
medium Vs. high doses. In the era when treat-to-target strategies have been proposed in order to 
control SLE disease activity, improve health-related quality of life, and reduce morbidity and mortality, 
using GCs in a more restrictive way should be a goal to prevent major complications in patients with 
SLE.  
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INTRODUCTION 
Glucocorticoids (GCs) are among the most potent immunosuppressive and anti-inflammatory drugs. 
Their efficacy in treating Systemic Lupus Erythematous (SLE) is beyond doubt. However, GC-related 
side effects are multiples and serious. Indeed, prednisone use has been consistently shown to increase 
irreversible damage in lupus patients, a major predictor of morbidity and mortality [1]. Despite the 
current available evidences suggesting to reduce daily doses of prednisone <7.5 mg/day, or even to 
withdraw it, sometimes physicians might struggle in achieving this goal. Among others, Gladman et al. 
when reporting on the course of an inception SLE cohort prospectively followed-up of at least 15 years 
showed that overall 87.7% of patients received GCs, at a mean maximum dose of 37.7 mg/day [2].  
Similarly, in the real-life practice, it is not uncommon to see patients receiving medium doses (up to 30 
mg/day) or high doses (≥30 mg/day). Adverse effects (AEs) of GC therapy, such as increased risk of 
infection, avascular osteonecrosis, osteoporosis, myopathy, diabetes mellitus or cushingoid features, 
as well as skin bruising and cataracts are known and have been well described, especially in studies 
conducted when GCs were among the few therapeutic tools for SLE management [1]. However, 
quantifying the risk of AEs related to medium or high dose of GCs is still challenging, especially in an 
era when patients are rarely receiving GCs alone.   
 
MATERIALS and METHODS 
When attempting to assess the rate of AEs related to medium or high dose of GCs in patients with SLE, 
using a pre-defined protocol, we systematically reviewed the literature selecting studies for evaluation 
when they met all of the following criteria: (i) Randomized Control Trials (RCTs), (ii) enrolled adult 
patients with SLE, (iii) at least one of the treatment groups includes corticosteroids alone at medium 
doses (up to 30 mg/day prednisone or equivalent) or high doses (≥30 mg/day prednisone or 
equivalent), (iii) reporting rate of GC-related side effects (including hypertension, diabetes, reduction 
in bone mass index/aseptic osteonecrosis). We searched the MEDLINE, EMBASE and CINAHL 
databases from their inception (starting in 1950) to December 2016. Medical subject headings (MeSH) 
terms used in the MEDLINE database search included ‘systemic lupus erythematosus’, 
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‘corticosteroids’, ‘glucocorticoids’. Index terms were modified appropriately for the other databases. 
The Cochrane Library (the Cochrane Central Register of Controlled Trials and the Cochrane Database 
for Systematic Reviews) was also searched. This was supplemented by manually searching 
bibliographies of these articles and of previously published reviews.  
Potential studies identified with the above search strategy were exported to an electronic reference 
management software program (RefWorks v.2.0). Duplicate studies were identified and removed 
using the filter functions “exact duplicates” and “close duplicates.” 
Quality assessments of the suitable RCTs and data extraction from them were done independently by 
two reviewers (E.M. and S.S.). In case of disagreement, consensus was aimed for and if it was not 
achieved, a third reviewer (M.J.C.) gave final judgment. It was pre-determined that the corresponding 
author of an included RCT would only be contacted if any data/information relevant to this meta-
analysis was found missing in the published RCT. 
We abstracted data for the AEs from every paper and entered them into a Microsoft Excel database. 
For the 8 retained studies [3–10], the extracted data included study characteristics (setting, duration, 
design, treatment/intervention, patients characteristic, AES rate and details).  
 
RESULTS AND DISCUSSION 
Out of one-hundred and two screened studies, a total of 8 RTCs [3–10] met the inclusion criteria, 
including 182 SLE patients receiving GCs alone at medium doses (up to 30 mg/day prednisone or 
equivalent) or high doses (≥30 mg/day prednisone or equivalent).  Study details, patients 
characteristics and treatments protocols are shown in Table 1. AEs for each study are described in 
Table 2. When pooling together the adverse events reported in studies and adjusting for treatment 
duration, we found a rate of 9/100patients/year for hyperglycaemias/diabetes, 25/100patients/year 
infections, and 12/100patients/year for avascular necrosis of the hip. Among the studies reporting the 
type of infection, respiratory tract and herpes zoster infections seemed the most frequently occurred.  
When adjusting for CGs dose (meant as prednisone equivalent, calculated according to Shimmer et al. 
[11]) and treatment duration, we observed no difference in terms of AEs rate comparing patients 
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receiving medium Vs. high doses. This observation is in line with the ideas that GCs-related AEs should 
be considered according to the level of activation of the genomic and non-genomic ways  (low doses , 
up to 7.5 mg/day Vs. medium-high doses, equal or higher than 30 mg/day)[12]. This aspect should be 
kept in mind when a steroid tapering scheme is planned, as it should aim to achieve dose <30 mg/dl to 
really impact on the rate of GCs-related AEs.   
Every effort should be made to avoid GC side effects. It should be remembered that medium to high 
GCs doses are not the therapy of lupus, but part of the treatment of few severe lupus manifestations. 
Concomitant use of immunosuppressive agents [13], biological drugs [14,15] and anti-malarials [16] 
may help keep daily doses of prednisone <7.5 mg/day, or even to withdraw it. In the era when treat-
to-target strategies have been proposed in order to control disease activity, improve health-related 
quality of life, and reduce morbidity and mortality, using GCs in a more restrictive way should be a 
goal to prevent major complications in patients with SLE.  
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Table 1: Characteristics of RCTs included in the systematic review 
Study 
(First 
Author, 
Year) 
RTC Country Inclusion Criteria Patients Age 
mean(range) 
Time 
receving 
GCs 
Diseases 
Duration of 
SLE 
mean(range) 
Steroids  
(Oral or 
IV) 
GCs Protocol 
Austin et 
al. (2009) 
Randomized, 
controlled trial of 
prednisone, 
cyclophosphamide, 
and cyclosporine in 
lupus membranous 
nephropathy.   
USA Membranous LN 
with  ≥2 g/d 
proteinuria 
42 (15 in 
the 
prednisone 
group) 
 40 yrs  
(13-60) 
1 yr 7 months (1 -
120) 
oral High-dosage 
alternate-day oral 
prednisone (initiated 
at 40 mg/m2 body 
surface area 
[approximately 1 
mg/kg body wt] 
every other day for 8 
wk, followed by 
gradual tapering [5 
mg/wk] to 10 
mg/m2 body surface 
area every other day 
for the remainder of 
the 1-yr protocol 
treatment period) 
 Barile-
Fabris et 
al. (2005) 
Controlled clinical 
trial of IV 
cyclophosphamide 
versus IV 
methylprednisolone 
in severe 
neurological 
manifestations in 
SLE.  
Mexico NPSLE 
manifestations* 
32 (Cy 
n=19; MP 
n=13) 
CyC arm: 33 
yrs (17–48);  
MP arm: 
26yrs 
(19–44) 
1 yr CyC arm 4.2 
(0.11–16);  
MP 2.5 (0–
12) 
oral and 
IV 
Basal prednisone 
dose (mg/day) mean 
(range): AT 
BASELINE: Cy 45 
(15–60); MP 45 (15–
60) 
Gourley 
et al. 
(1996)  
Methylprednisolone 
and 
cyclophosphamide, 
alone or in 
combination, in 
patients with LN.  
USA LN 82  
(MP arm, 
n=27;  
CyC arm, 
n=27; 
MP+CyC 
arm, n=28) 
MP arm: 30;  
CyC arm:30; 
MP+CyC 
arm: 31 
1 yr MP arm: 31 ± 
8.6 months;  
CyC arm: 24 
± 6.9 
months;  
MP+CyC arm 
39 ± 13.6 
months 
oral and 
iv 
IV: Bolus therapy 
with MP (1 g/m2 
body surface area), 
given monthly for at 
1 year.                                                                                                                                                                                                                                                          
ORAL: 0.5 mg/kg per 
day for 4 weeks. The 
prednisone dose 
was then tapered by 
5 mg every other 
day each 
week to the minimal 
dose of 0.25 mg/kg 
every other day  
 Belmont 
et al. 
(1995) 
Misoprostol and 
prednisone 
treatment of LN.  
USA LN 14 35 ± 2 (range 
26-55) 
3 
months 
N/R oral Oral prednisone 1 
mg/kg/day during 8 
weeks. After that, 
the steroid dose was 
tapered by 10 mg 
every 2 weeks for 
the next 4 weeks                                                                                                                                                                                                    
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Barron et 
al. (1982) 
Pulse 
methylprednisolone 
therapy in diffuse 
proliferative lupus 
nephritis. 
USA LN  22 (high 
dose group 
n=15; pulse 
group n=7) 
N/R 1 yr Age of onset 
(yr): pulse 
11.4 ± 3.6; 
high dose 
11.9 ± 2.9 
oral and 
IV 
HIGH-DOSE group: 
prednisone oral 
starting at 2 
mg/kg/day for a 3-6 
months and then 
reduced gradually 
over the next several 
months.                                                   
PULSE group:  6 
times 30 mg/kg 
body weight of 
methylprednisolone 
(maximum 1 gm) 
followed by 
prednisone 2 
mg/kg/day  
Boumpas 
et al. 
(1992) 
Controlled trial of 
pulse 
methylprednisolone 
versus two regimens 
of pulse 
cyclophosphamide in 
severe lupus 
nephritis 
 USA Severe LN 65 N/R  3 
months 
33 months IV IV of 1.0 g/m2 
methylprednisolone 
over initially in three 
daily doses, followed 
by monthly single 
doses 
for 6 months  
Edwards 
et al. 
(1987) 
Double blind 
controlled trial of 
methylprednisolone 
infusions in SLE using 
individualised 
outcome assessment 
UK Severe SLE  20 N/R 6 
months 
 N/R IV 3  daily infusions of 
either 100 mg or 1 g 
of 
methylprednisolone  
+ a mean of 
7mg/day prednisone 
Hahn et 
al. (1975) 
Azathioprine plus 
prednisone 
compared with 
prednisone alone in 
the treatment of 
SLE. Report of a 
prospective 
controlled trial in 24 
patients 
USA Severe SLE 13 31  3 
months 
 N/R oral Prednisolone 60 
mg/day  
 
GCs, glucorticoids; LN, lupus nephritis; SLE, Systemic Lupus Erythematosus; NPSLE, Neuropsychiatric  Systemic Lupus Erythematosus ; IV, 
intravenous infusion; CyC, cyclophosphamide;  MP, methylprednisolone; N/R, not reported; *peripheral/cranial neuropathy, optic neuritis, 
transverse myelitis, brainstem disease, refractory seizures or coma 
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Table 2: Adverse Effects reported in each RTC included in the systematic review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GCs, glucorticoids; N/R, not reported; *other infections included sinusitis, bronchitis, otitis media, dental abscess, upper respiratory tract infection, 
sty, pelvic inflammatory disease, cholecystitis, and herpes simplex virus skin infection); ** not distinguishing between severe osteoporosis/avascular 
necrosis of the hip 
 
 
 
 
 
 
 
 
 
 
 
Study (First 
Author, Year) 
Patients  
Receiving 
CGs 
alone 
Diabetes/Hyperglycaemia Infections 
Avascular necrosis 
of the hip 
Other AEs 
Austin et al. 
(2009) 
15 1 Diabetes 
1 pneumonia, 3 
other infections* 
4** N/A 
 Barile-Fabris 
et al. (2005) 
13 1 Hyperglycaemia 
8 Urinary tract and 4 
respiratory 
infections 
N/R Pancreatitis  
Gourley et al. 
(1996)  
27 N/R 
1 herpes zoster, 2 
other infections 
6 Avascular 
Necrosis 
2 Amenorrhea 
 Belmont et 
al. (1995) 
7 N/R 1  N/R N/A 
Barron et al. 
(1982) 
22 N/R N/R  3 Aseptic necrosis         N/A 
Boumpas et 
al. (1992) 
65 N/R 3 herpes zoster 
3/17 
osteonecrosis 
6 cataracts 
Edwards et 
al. (1987) 
20 
 Raised serum glucose 
levels were 
transient and not 
associated with 
symptoms. 
N/R N/R 
Blood pressure rose temporarily in 
some patients 
but did not require treatment  
Hahn et al. 
(1975) 
13 7 hyperglycaemia 7 1 Aseptic necrosis    
11 Cushingoid habitus; 11 
hypertension; 6  hypokalemia 
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